Serum peptidomic screening identified circulating peptide biomarkers predictive for preeclampsia

Shenglong Zhao, Chenghong Yin, Yanhong Zhai, Zhaoxia Jia, Shaofei Su, Yifan Lu, Lanlan Meng, Chunbo Li, Xiang Liu, Yuting Cong, Youran Li, Ying Liu, Lu Chen, Jing Wang, Zhengwen Xu, Yuanyuan Zheng, Sun Zhi, Ruben Yiqi Luo, Xiaobo Yu, He S. Yang, Xiaowei Liu, Zhen Zhao, Zheng CaoFrontiers in Cardiovascular Medicine 2022 · DOI

TL;DR

Researchers have identified a novel three-peptide panel in maternal serum that can accurately predict the development of preeclampsia (PE) in pregnant women. This discovery offers a promising new tool for early detection and management of this serious pregnancy complication, potentially improving outcomes for both mother and child.

What Problem Does This Paper Address?

Preeclampsia (PE) is a dangerous pregnancy complication characterized by high blood pressure and organ damage, posing significant risks to pregnant individuals and their babies, including preterm birth and mortality. Despite its prevalence, reliable early warning indicators for PE are lacking, making timely diagnosis and intervention challenging. Current diagnostic methods often have low positive predictive values, leading to unnecessary interventions for many. This paper aims to address this critical gap by identifying and validating novel, accurate serum biomarkers for PE prediction, particularly in women already showing symptoms or abnormal lab results suggestive of PE.

Methods

The study employed a two-phase approach: discovery and validation.

  • Discovery Phase: Serum samples from pregnant women with suspected PE were analyzed using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) coupled with high-resolution mass spectrometry. This peptidomic approach allowed for the unbiased screening of a wide range of naturally occurring peptides.
  • Candidate Identification: Differentially expressed peptides between PE-positive and PE-negative groups were identified.
  • Verification and Quantitation: Promising peptide candidates were then verified and quantitatively measured using an in-house developed liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. This allowed for precise measurement of peptide levels.
  • Validation Phase: The identified peptide biomarkers were further validated in an independent cohort of pregnant women to confirm their predictive performance.

Datasets

The study utilized serum samples from pregnant women:

  • Discovery Cohort: 115 pregnant women (30 PE-positive, 85 PE-negative) were included for peptide biomarker discovery and verification.
  • Validation Cohort: An independent cohort of 80 pregnant women (20 PE-positive, 60 PE-negative) was used for peptide biomarker validation.

The study did not introduce new benchmark datasets but rather used prospectively collected samples from a specific clinical setting.

Key Insights and Ideas

  • Peptidomics as a Powerful Tool: The study highlights the effectiveness of peptidomics, the study of endogenous peptides, in identifying novel biomarkers for complex diseases like PE. By focusing on peptides, which are biologically active fragments, researchers can uncover subtle changes that might be missed by broader proteomic analyses.
  • Three-Peptide Panel Synergy: The most significant insight is the discovery that a combination of three specific peptides (derived from Fibrinogen alpha chain (FGA), Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), and Complement component 3 (C3)) demonstrates superior predictive power for PE compared to individual peptides or existing markers like the sFlt-1/PIGF ratio.
  • Early Predictive Signal: The identified peptide changes appear to precede the clinical onset of PE, suggesting they could serve as early warning signals.
  • Improved "Rule-In" and "Rule-Out" Capabilities: The developed three-peptide panel shows significantly improved positive predictive values (PPV) compared to the sFlt-1/PIGF ratio, making it more effective for "ruling in" high-risk individuals and potentially reducing unnecessary interventions.

Key Results

  • Biomarker Identification: Eight differentially expressed peptides were identified, originating from FGA, ITIH4, and C3.
  • Three-Peptide Panel Performance (Discovery Cohort): The combined three-peptide panel achieved an Area Under the Receiver Operating Characteristic Curve (AUC) of 0.985, with a sensitivity of 96.7% and a specificity of 94.1%.
  • Three-Peptide Panel Performance (Validation Cohort): In the independent validation cohort, the panel demonstrated a strong AUC of 0.923, with a sensitivity of 95.0% and a specificity of 88.3%.
  • Superiority over Existing Markers: The three-peptide panel significantly outperformed the sFlt-1/PIGF ratio in predictive accuracy in both cohorts. For instance, in the discovery cohort, the sFlt-1/PIGF ratio had an AUC of 0.637, while the combined peptide panel achieved 0.985.
  • Correlation Analysis: The study found slight negative correlations between the identified peptides and serum PIGF, and marginally positive correlations with the sFlt-1/PIGF ratio. No significant correlation was observed with age, pre-pregnancy BMI, gravidity, or parity.

Limitations and Future Work

  • Ethnic Diversity: The study participants were exclusively Chinese. The authors acknowledge that the performance of this peptide panel in diverse ethnic backgrounds, particularly in Western populations, needs to be further tested.
  • Cohort Size and Site: The study cohorts were relatively small and drawn from a single clinical site. Future work should involve larger, multi-center studies to confirm these findings and establish robust cut-off values for clinical application.
  • Pathological Mechanism: While the study identifies predictive peptides, the exact biological roles of FGA and ITIH4 in the pathogenesis of PE remain largely unknown and require further investigation.
  • Clinical Implementation: The authors suggest that with the development of a straightforward LC-MS/MS quantitation method, these circulating peptides could be integrated into clinical practice for PE prediction.

Summary updated

Abstract

We have discovered and validated a novel three-peptide biomarker panel predictive for the occurrence PE in pregnant women.
BibTeX
@inproceedings{zhao2022serum,
  author = {Shenglong Zhao and Chenghong Yin and Yanhong Zhai and Zhaoxia Jia and Shaofei Su and Yifan Lu and Lanlan Meng and Chunbo Li and Xiang Liu and Yuting Cong and Youran Li and Ying Liu and Lu Chen and Jing Wang and Zhengwen Xu and Yuanyuan Zheng and Sun Zhi and Ruben Yiqi Luo and Xiaobo Yu and He S. Yang and Xiaowei Liu and Zhen Zhao and Zheng Cao and Zhen Zhao and Zheng Cao},
  title = {{Serum peptidomic screening identified circulating peptide biomarkers predictive for preeclampsia}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.946433},
}
Figure